Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Recent & Breaking News (TSX:GUD)

Second Leading Proxy Advisor Rejects Meir Jakobsohn's Attempt to Take Control of Knight Therapeutics' Board

GlobeNewswire April 26, 2019

Knight to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference in Toronto

GlobeNewswire April 26, 2019

Leading Independent Proxy Advisor, Key Shareholders, and More Analysts Back Jonathan Goodman's Knight, Recommend Meir Jakobsohn Not be Re-elected to the Board

GlobeNewswire April 25, 2019

Leading Independent Proxy Advisory Firm ISS Recommends Change at Knight Therapeutics

Canada NewsWire April 25, 2019

Knight Therapeutics Releases New Letter to Shareholders, Reminds Shareholders of Important Vote

GlobeNewswire April 25, 2019

Medison Issues Presentation to Knight Shareholders

Canada NewsWire April 18, 2019

Leading Canadian Corporate Governance Expert Confirms Acute Board Conflicts and Governance Deficiencies at Knight Therapeutics

Canada NewsWire April 17, 2019

Medison Issues Letter to Shareholders of Knight Therapeutics, Outlining Qualified, Independent Director Nominees and Common-Sense Plan to Build Value

Canada NewsWire April 16, 2019

Knight Therapeutics: Use of PROBUPHINE™ for Opioid Disorder Gains Momentum Across Canada; Subdermal Implant Now in Use from Coast to Coast

GlobeNewswire April 12, 2019

Knight Therapeutics: Use of PROBUPHINE(TM) for Opioid Disorder Gains Momentum Across Canada; Subdermal Implant Now in Use from Coast to Coast

GlobeNewswire April 12, 2019

Knight Receives Unanimous Support from Independent Analysts for Director Nominees, Current Strategy

GlobeNewswire April 10, 2019

Medison Disappointed that Knight Therapeutics has Resorted to Blatant Misrepresentations to Avoid Scrutiny

Canada NewsWire April 10, 2019

Medison Files Proxy Circular, Offers Knight Therapeutics Shareholders Truly Independent, Unconflicted Directors and Comprehensive Business Plan to Fix a Failing Knight

Canada NewsWire April 8, 2019

Knight Therapeutics Continues to Demonstrate Winning Strategy; Files Investor Presentation, Launches Microsite

GlobeNewswire April 8, 2019

Knight Files Management Information Circular, Warns Shareholders of Activist Jakobsohn’s Self-Interested Agenda

GlobeNewswire April 4, 2019

Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders

Canada NewsWire April 1, 2019

Knight Therapeutics Initiates Legal Action Against Medison Biotech to Protect the Interests of Knight Shareholders

GlobeNewswire March 21, 2019

Knight Therapeutics Responds to Shareholder Discontent By Targeting Medison Biotech, Knight’s Second Largest Shareholder

GlobeNewswire March 15, 2019

Knight Addresses Misleading and Self-Serving Plan Issued by Disgruntled Director

GlobeNewswire March 14, 2019

Knight Therapeutics’ Second Largest Shareholder Presents Strategy to Create Shareholder Value

GlobeNewswire March 14, 2019